Polycythemia Vera: Barriers to and Strategies for Optimal Management

Abstract

Polycythemia vera (PV) is a subtype of myeloproliferative neoplasms characterized by impaired quality of life and severe complications. Despite the increasingly in-depth knowledge of this condition, it necessitates a multifaceted management approach to mitigate symptoms and prevent thrombotic and hemorrhagic events, ensuring prolonged survival. The therapeutic landscape has been revolutionized in recent years, where venesection and hydroxycarbamide associated with antiplatelet therapy have a central role and are now accompanied by other drugs, such as interferon and Janus kinase inhibitors. Ongoing research and advancements in targeted therapies hold promise for further enhancing the therapeutic choice for PV management.

Keywords:

• polycythemia vera
• barriers to treatment
• current approach
• future perspectives

Disclosure

Andrea Duminuco reports personal fees from BMS Celgene, personal fees from Incyte, personal fees from EusaPharma, outside the submitted work. Patrick Harrington reports grants from Bristol Myers Squibb, personal fees from Incyte, outside the submitted work. Claire Harrison reports grants, personal fees and travel support from Novartis, grants, personal fees from Constellation, grants, personal fees from Celgene/BMS, personal fees, non-financial support from AbbVie, grants, personal fees from AOP, grants, personal fees from CTI/Sobi, grants, personal fees from IMAGO/MSD, personal fees from Galecto, personal fees from Geron, personal fees from Keros, grants, personal fees, and writing from GSK, outside the submitted work; and Work with European Haematology Association Work with patient advocacy – Blood Cancer UK, MPN Voice. The authors report no other conflicts of interest in this work.